AI Article Synopsis
- - The study focused on enhancing clinical decision support systems (CDSS) by creating a new tool, TLC-Act, to help pharmacists manage drug-drug interactions (DDIs) based on their clinical reasoning rather than relying solely on existing systems.
- - The research involved developing the tool, implementing it in practice, and gathering feedback from pharmacy residents through an online survey, with validation conducted via simulations prior to implementation.
- - Results showed that 73% of the pharmacy residents who responded to the survey found TLC-Act to be more useful than traditional CDSS for assessing DDIs, highlighting its alignment with how pharmacists think clinically.
Article Abstract
Background: Clinical decision support systems (CDSS) are used by pharmacists to assist in managing drug-drug interactions (DDIs). However, previous research suggests that such systems may perform suboptimally in providing clinically relevant information in practice.
Objectives: The primary objective of this study was to develop a novel DDI management tool to reflect the clinical thought process that a pharmacist uses when assessing a DDI. The secondary objective was to investigate practitioners' perceptions of this tool.
Methods: This study was conducted in 3 phases: development of the DDI management tool, implementation of the tool in clinical practice, and collection of practitioners' opinions of the tool through an online qualitative survey (although because of circumstances related to the COVID-19 pandemic, the study population for the survey phase included only pharmacy residents). A comprehensive literature search and analysis by an expert panel provided underlying context for the DDI management tool. The tool was validated through simulation against a known list of DDIs before implementation into practice by hospital pharmacists and pharmacy residents. Participating pharmacy residents were invited to provide feedback on the tool. Survey results were analyzed using descriptive statistics.
Results: The novel tool that was developed in this study (called TLC-Act) consisted of components important to a pharmacist when assessing a DDI, including the duration of concomitant use of the interacting medications and patient-specific risk factors. Study participants implemented the tool in clinical practice for a total of 6 weeks. Of the 28 pharmacy residents surveyed, 15 (54%) submitted a response, of whom 11 (73%) found the TLC-Act tool to be slightly more useful for assessing a DDI than usual care with the CDSS alone.
Conclusions: The TLC-Act tool maps out a pharmacist's clinical thought process when assessing a DDI in practice. This novel tool may be more useful than a CDSS alone for managing DDIs, as it takes into account other important factors pertinent to the assessment of a DDI.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245403 | PMC |
| http://dx.doi.org/10.4212/cjhp.3171 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Positioning Enzyme- and Transporter-Based Precipitant Drug-Drug Interaction Studies in Drug Design.
J Med Chem
January 2025
Department of Pharmacokinetics Dynamics & Metabolism, Pfizer Inc., Groton, Connecticut 06340, United States.
assessment of the potential of compounds to affect drug metabolizing enzymes and transporters and perpetrate drug-drug interactions (DDIs) is a common practice in drug research. For the development phase, regulators define an exhaustive list of enzymes and transporters to consider, but DDIs associated with many of these are minor and can be well-managed in the clinic; thus, progression of drug candidates that address unmet medical needs should not be curtailed due to this property. However, some enzymes and transporters are very important in drug disposition, so it is important to avoid/reduce inhibition or induction of these through drug design.
View Article and Find Full Text PDFSevere Impact of Omeprazole Timing on pH-Sensitive Dasatinib Absorption: Unveiling Substantial Drug-Drug Interaction.
J Clin Pharmacol
December 2024
Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Uppsala, Sweden.
The absorption and bioavailability of most tyrosine kinase inhibitors are affected by gastrointestinal pH as they are weak basic lipophilic drugs. Hence, concomitant use of acid reducing agents (ARAs) is frequently restricted. Particularly comedication of crystalline dasatinib (Sprycel) and proton-pump inhibitors (PPIs) should be avoided.
View Article and Find Full Text PDFEvaluation of BCRP-Related DDIs Between Methotrexate and Cyclosporin A Using Physiologically Based Pharmacokinetic Modelling.
Drugs R D
December 2024
Galapagos SASU, Romainville, France.
Background And Objective: This study provides a physiologically based pharmacokinetic (PBPK) model-based analysis of the potential drug-drug interaction (DDI) between cyclosporin A (CsA), a breast cancer resistance protein transporter (BCRP) inhibitor, and methotrexate (MTX), a putative BCRP substrate.
Methods: PBPK models for CsA and MTX were built using open-source tools and published data for both model building and for model verification and validation. The MTX and CsA PBPK models were evaluated for their application in simulating BCRP-related DDIs.
Impact of Immune Abnormalities on COVID-19 Vaccine Effectiveness in Infected Patients.
Cureus
November 2024
Pulmonary and Critical Care Medicine, Foshan Sanshui District People's Hospital, Foshan, CHN.
Objective To assess the protective effect of COVID-19 vaccines in patients with varying immune states by analyzing lactate dehydrogenase (LDH), C-reactive protein (CRP), and D-dimer (D-Di) levels in COVID-19-infected individuals under different vaccination scenarios and immune statuses. Methods This is a single-center retrospective study involving 338 SARS-CoV-2-infected patients treated at a tertiary medical center in Foshan, China, between November 2022 and January 2023. The primary outcome was the vaccine's protective effect on LDH, CRP, and D-Di levels.
View Article and Find Full Text PDFEfficient analysis of drug interactions in liver injury: a retrospective study leveraging natural language processing and machine learning.
BMC Med Res Methodol
December 2024
Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Background: Liver injury from drug-drug interactions (DDIs), notably with anti-tuberculosis drugs such as isoniazid, poses a significant safety concern. Electronic medical records contain comprehensive clinical information and have gained increasing attention as a potential resource for DDI detection. However, a substantial portion of adverse drug reaction (ADR) information is hidden in unstructured narrative text, which has yet to be efficiently harnessed, thereby introducing bias into the research.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!